Humoral response against sialyl-Le(a) glycosylated protein species in esophageal cancer: Insights for immunoproteomic studies.
Esophageal cancers (ECs) show poor prognosis and decreased overall survival due to late diagnosis and ineffective therapeutics, urging the introduction of novel biomarkers to aid disease management. The levels of sialyl-Lewis(a) antigen (sLe(a) ) are frequently increased in digestive tumours, which has been explored in serological non-invasive prognostication (CA19-9 test); however, with low sensitivity and specificity. Autoantibodies against cancer antigens are considered the next generation biomarkers, as they are present in circulation long before tumour-associated proteins. Based on these observations we have mined the serum of EC patients (n = 7) for antibodies against sLe(a) -glycosylated protein species. All EC were positive for sLe(a) , irrespectively of their histological nature but only two patients showed elevated CA19-9. Moreover, IgG titers, with emphasis on IgG1, were elevated in EC patients in comparison to the control group. SLe(a) -glycoproteins were then extracted from tumours of patients with negative CA19-9, isolated by immunoprecipitation and blotted with patients IgG. Autoantibodies against sLe(a) -glycosylated proteins were detected in all cases. Different SLe(a) -glycoproteins were observed for tumours of distinct histological natures, which now require identification and validation in larger patient sets. This preliminary data suggests that antoantibodies against sLe(a) glycosylated proteins hold potential for non-invasive diagnosis in CA19-9 negative cases and sets the rational for future immunoproteomic studies envisaging highly specific EC biomarkers.
Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal.|Institute of Biomedical Sciences of Abel Salazar, University of Porto, Porto, Portugal.
Elisabete
E
Fernandes
Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal.
Andreia
A
Peixoto
Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal.
Manuel
M
Neves
Department of Pathology, Portuguese Institute of Oncology of Porto, Porto, Portugal.
Luís Pedro
LP
Afonso
Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal.|Health School of University of Fernando Pessoa, Porto, Portugal.|Department of Surgical Oncology, Portuguese Institute for Oncology, Porto, Portugal.
Lúcio Lara
LL
Santos
Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal.|Mass Spectrometry Centre, QOPNA, Department of Chemistry of the University of Aveiro, Aveiro, Portugal.
José Alexandre
JA
Ferreira
D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology / Q000378:metabolism; D018395:CA-19-9 Antigen / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000276:immunology*; D005732:Gangliosides / Q000378:metabolism*; D006023:Glycoproteins / Q000276:immunology* / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged
D001323:Autoantibodies; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D005732:Gangliosides; D006023:Glycoproteins; D007074:Immunoglobulin G; C064564:sialyl Le(a) ganglioside
Autoantibodies; Cancer immunology; Cancer-associated carbohydrate antigens; Glycans; Humoral response; Sialyl-Lewis(a)